Surrogate endpoints are often called biomarkers or surrogates.
- Surrogate endpoints are validated measures backed by science.
- Surrogate endpoints measure outcomes that are reasonably likely to predict clinical benefit.
- Allow for shorter clinical trials and earlier access to treatments when, in many cases, a clinical outcome such as survival or lung function would take months or years to demonstrate.
- Can have advantages over the use of clinical outcomes. In many diseases, surrogate endpoints (biomarkers) can more accurately capture real-time disease progression or improvement.
https://everylifefoundation.org/accelerated-approval/